You are here:

indacaterol (Onbrez Breezhaler)

Advice

following a full submission

indacaterol (Onbrez Breezhaler)

is accepted for use within NHS Scotland.

Indication under review: maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).

Indacaterol has been found to be statistically superior to placebo and other long-acting bronchodilators in improving lung function (FEV1) after 12 weeks.

Another long-acting beta2 agonist is available at lower cost. 

Drug Details

Drug Name: indacaterol (Onbrez Breezhaler)
SMC Drug ID: 619/10
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD)
BNF Category:
Sub Category: N/A
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 August 2010

Back